Behavioral Activation - From Inpatient to Outpatient Services

NCT ID: NCT01786733

Last Updated: 2017-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effectiveness of Behavioral Activation and Supportive Therapy added to the standard acute psychiatric inpatient care. Therapy starts during inpatient care and can continue in an outpatient facility if the patients are discharged before 12 sessions has been completed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psychiatric inpatient care is reserved for individuals with the most acute mental health problems. The period after discharge is associated with increased risk for relapse, non-adherence and suicide. Delivering high quality psychosocial interventions during and after acute psychiatric inpatient care is known to be a difficult challenge. This study will investigate the effectiveness of adding either Behavioral Activation or Supportive Therapy to the standard acute psychiatric inpatient care. Subjects with different psychiatric diagnoses and elevated depressive symptoms are assessed and randomized after admission. Therapists from the nearest outpatient facility initiate 12 sessions of Behavioral Activation or Supportive Therapy as soon as possible. The 12 sessions are delivered twice weekly at the inpatient unit or at the outpatient facility, depending on whether the patient is admitted or discharged. Treatment as usual interventions(medications, nursing etc.) are not manipulated in the study. The main assessment points are pre-, post, 6 months follow-up and 12 months follow-up. The main outcome measure and some process measures are also administered at session 3, 6 and 9.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inpatient Facility Diagnoses Psychiatric Disorders Depressive Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Behavioral Activation

Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.

Group Type EXPERIMENTAL

Behavioral Activation

Intervention Type BEHAVIORAL

Supportive Therapy

Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.

Group Type ACTIVE_COMPARATOR

Supportive Therapy

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Behavioral Activation

Intervention Type BEHAVIORAL

Supportive Therapy

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted into one of four acute psychiatric inpatient units in Dalarna
* MADRS-S 20 and above at acute admission and and after 2-3 days on the ward
* Psychiatric disorder according to M.I.N.I (Sheehan et al., 1998)
* Read and Speak Swedish

Exclusion Criteria

* Acute psychotic symptoms
* Acute manic symptoms
* Confusion
* Primary eating disorder
* Primary alcohol or substance abuse disorder
* Self rated score on AUDIT (Saunders et al., 1993)of 20 or greater
* Mental retardation
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fredrik Folke

PhD-student

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Per Söderberg, PhD

Role: STUDY_DIRECTOR

The Adult Psychiatric Clinic of Landstinget Dalarna, Sweden

Lisa Ekselius, Professor

Role: STUDY_CHAIR

Department of Neuroscience, Psychiatry, Uppsala University, Sweden

Stefan Tungström, PhD

Role: STUDY_CHAIR

The Adult Psychiatric Clinic of Landstinget Dalarna, Sweden

Timo Hursti, PhD

Role: STUDY_CHAIR

The Department of Psychology, Uppsala University, Sweden

Fredrik Folke, PhD-student

Role: PRINCIPAL_INVESTIGATOR

Department of Neuroscience, Psychiatry, Uppsala University, Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dnr 2012 / 226

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Women's Depression Treatment Study
NCT00843700 COMPLETED PHASE2
Behavioral Activation With Depressed Adolescents
NCT01137149 UNKNOWN PHASE1/PHASE2